Micrograph of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Credit: Nephron.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest Covid-19 updates on our timeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Amid the ongoing Covid-19 pandemic, Genfit is monitoring the impact on regulatory and clinical activities associated with its existing programmes.

The company does not expect any significant delay in the interim data readout of its Phase III RESOLVE-IT clinical trial of elafibranor involving patients suffering from non-alcoholic steatohepatitis with fibrosis.

According to Genfit, around 1,000 initial participants needed for regulatory approval have undergone their final visits. The cohort’s database was locked in February.

The unblinding of the study and interim data reporting will be based on the receipt and integration of insight from the US Food and Drug Administration (FDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genfit also decided to continue the extension phase of RESOLVE-IT trial. The company adopted certain safety measures for patients, including virtual clinic visits and home delivery of study drug.

However, the screening of new participants has been temporarily suspended.

The company placed on hold all Phase I trials, including pharmacokinetic, food effect and bioequivalence studies. Genfit said that these trials are required for filing elafibranor’s NDA in NASH indication.

Other trials on hold are the pharmacokinetic/pharmacodynamic paediatric NASH study and the Phase II liver fat study.

The company’s NASH combination and PBC programmes are being continued, and the launch of Phase II combination trial and Phase III PBC trial are on hold.

The company said in a statement: “All supporting activities pertaining to continuation of ongoing studies or the initiation of new studies will continue in order to minimise potential delays when the pandemic crisis subsides.”

The company is not currently expecting any supply disruption for studies but will continue to monitor the situation. It has enough elafibranor supply for all studies up to mid-2021.